aspirin has been researched along with Adenocarcinoma in 151 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 9.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC)." | 8.91 | Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. ( Cai, J; Li, P; Shi, Y; Wu, H; Wu, Y; Xia, D; Xu, J; Yang, J; Ye, Y; Zhang, H, 2015) |
| "The role of aspirin use in chemoprevention of esophageal adenocarcinoma (EAC) is still unclear." | 8.90 | The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. ( Pengcheng, X; Sidong, C; Weidong, L; Xiaohua, Y; Zhenjiang, Y, 2014) |
| "Prospective data examining the association of aspirin use, according to dose and duration, with long-term risk of gastric adenocarcinoma in non-Asian cohorts are lacking." | 8.12 | Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. ( Bao, Y; Cao, Y; Chan, AT; Drew, DA; Flynn, JJ; Fuchs, CS; Giovannucci, EL; Klempner, SJ; Kwon, S; Leonardo, BM; Ma, W; Song, M, 2022) |
| "Low-dose aspirin use may reduce cancer incidence and mortality, but its influence on gastric adenocarcinoma survival is unclear." | 8.12 | Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma. ( Asplund, J; Holmberg, D; Kauppila, JH; Lagergren, J; Leijonmarck, W; Mattsson, F; Xie, SH, 2022) |
| " We hypothesized that blood platelet count would be associated with systemic inflammation, the densities of tumor infiltrating immune cells, and survival in colorectal cancer (CRC), and these relationships could be altered by aspirin use." | 7.91 | Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. ( Herzig, KH; Karhu, T; Karttunen, TJ; Klintrup, K; Mäkelä, J; Mäkinen, MJ; Minkkinen, I; Sirniö, P; Tuomisto, A; Väyrynen, JP; Väyrynen, SA, 2019) |
| "Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear." | 7.91 | Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019) |
| "Meta-analyses have demonstrated that low-dose aspirin reduces the risk of developing adenocarcinoma metastasis, and when colon cancer is detected during aspirin treatment, there is a remarkable 83% reduction in risk of metastasis." | 7.83 | Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. ( Adler, D; Amin, T; Boutaud, O; Crews, BC; Harris, BK; Hoeksema, M; Hwang, HS; Knollmann, BC; Lammers, PE; Marnett, LJ; Massion, PP; Milne, G; Oates, JA; Oram, D; Sosa, IR, 2016) |
| "Aspirin use reduces colorectal cancer risk." | 7.83 | Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. ( Cao, Y; Chan, AT; Drew, DA; Fuchs, CS; Garrett, WS; Giovannucci, EL; Inamura, K; Lochhead, P; Mima, K; Morikawa, T; Nishihara, R; Nosho, K; Nowak, JA; Ogino, S; Qian, ZR; Song, M; Wang, M; Wu, K; Zhang, X, 2016) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 7.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 7.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| ": To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments." | 7.75 | Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. ( Hongwei, L; Shu, L; Xiaoxin, M; Yanxia, L; Yingnan, J; Yuanqi, H, 2009) |
| "To investigate the inhibitory effect of arsenic trioxide, aspirin and their combination on the growth of human gastric adenocarcinoma SGC-7901 graft in nude mice." | 7.75 | [Effect of arsenic trioxide combined with aspirin on the growth of human gastric adenocarcinoma graft in nude mice]. ( Liu, H; Qiu, J; Wu, YP, 2009) |
| "Human esophageal adenocarcinoma cells were treated 18 hours with 50-300 muM deoxycholic acid, chenodeoxycholic acid, or taurocholic acid." | 7.74 | Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. ( Geng, J; Gong, J; Song, Y; Wu, J, 2008) |
| " We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines." | 7.72 | NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. ( Amadori, D; Medri, L; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W, 2003) |
| " Epidemiologic and experimental studies suggest that regular use of aspirin may reduce colorectal cancer risk." | 7.70 | Aspirin use and p53 expression in colorectal cancer. ( Asirwatham, JE; Caporaso, NE; Freedman, AN; Marshall, JR; Mettlin, CJ; Michalek, AM; Petrelli, NJ; Weiss, HA; Zhang, ZF, 1998) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 5.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "Current available therapies for pancreatic ductal adenocarcinoma (PDAC) provide minimal overall survival benefits and cause severe adverse effects." | 5.62 | Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. ( Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK, 2021) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 5.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 5.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "Aspirin has also been shown to inhibit cell proliferation in human tumor cell lines and to induce apoptosis in colonic mucosa of familial polyposis patients." | 5.30 | Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. ( Acquaviva, AM; Apicella, A; Di Popolo, A; Memoli, A; Pignata, S; Ricchi, P; Zarrilli, R, 1997) |
| " These occurred only in the groups given MNNG in combination with stress, aspirin, or sodium taurocholate, and did not occur in experimental groups given either MNNG, stress, aspirin, or sodium taurocholate alone, and did not occur in the control group." | 5.27 | Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N'-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. ( Cohen, A; Geller, SA; Horowitz, I; Toth, LS; Werther, JL, 1984) |
| "311 subjects with single/multiple colorectal adenomas and adenocarcinomas excised by endoscopy were enrolled in the study (152 patients in the aspirin group and 159 patients in the placebo group)." | 5.19 | The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. ( Abe, T; Gondo, N; Goto, C; Iimuro, M; Ishikawa, H; Joh, T; Kitamura, S; Kudo, SE; Kusunoki, M; Lee, K; Matsuda, T; Matsuura, N; Mizuno, M; Mutoh, M; Okamura, S; Saida, Y; Sakai, T; Sano, Y; Sato, Y; Sugimoto, K; Suzuki, S; Tajika, M; Takayama, T; Tanaka, S; Tokudome, S; Wakabayashi, K; Yukawa, T, 2014) |
| "We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia." | 5.14 | A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009) |
| "The objective of this meta-analysis was to systematically assess the survival benefit of aspirin use before or after diagnosis for patients with colorectal cancer (CRC)." | 4.91 | Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. ( Cai, J; Li, P; Shi, Y; Wu, H; Wu, Y; Xia, D; Xu, J; Yang, J; Ye, Y; Zhang, H, 2015) |
| "The role of aspirin use in chemoprevention of esophageal adenocarcinoma (EAC) is still unclear." | 4.90 | The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis. ( Pengcheng, X; Sidong, C; Weidong, L; Xiaohua, Y; Zhenjiang, Y, 2014) |
| "Daily aspirin reduces the long-term incidence of some adenocarcinomas, but effects on mortality due to some cancers appear after only a few years, suggesting that it might also reduce growth or metastasis." | 4.88 | Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. ( Belch, JF; Meade, TW; Mehta, Z; Price, JF; Rothwell, PM; Wilson, M, 2012) |
| " However, among former aspirin users and never smokers, there could be a reduction of gastric distal adenocarcinoma risk with a higher adherence to a Mediterranean diet." | 4.31 | Diet quality and risk of gastric adenocarcinoma: The Multiethnic Cohort. ( Acuna, N; Boushey, C; Hébert, JR; Le Marchand, L; Park, SY; Setiawan, VW; Wilkens, LR; Wu, AH, 2023) |
| "Low-dose aspirin use may reduce cancer incidence and mortality, but its influence on gastric adenocarcinoma survival is unclear." | 4.12 | Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma. ( Asplund, J; Holmberg, D; Kauppila, JH; Lagergren, J; Leijonmarck, W; Mattsson, F; Xie, SH, 2022) |
| "Prospective data examining the association of aspirin use, according to dose and duration, with long-term risk of gastric adenocarcinoma in non-Asian cohorts are lacking." | 4.12 | Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study. ( Bao, Y; Cao, Y; Chan, AT; Drew, DA; Flynn, JJ; Fuchs, CS; Giovannucci, EL; Klempner, SJ; Kwon, S; Leonardo, BM; Ma, W; Song, M, 2022) |
| " We hypothesized that blood platelet count would be associated with systemic inflammation, the densities of tumor infiltrating immune cells, and survival in colorectal cancer (CRC), and these relationships could be altered by aspirin use." | 3.91 | Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer. ( Herzig, KH; Karhu, T; Karttunen, TJ; Klintrup, K; Mäkelä, J; Mäkinen, MJ; Minkkinen, I; Sirniö, P; Tuomisto, A; Väyrynen, JP; Väyrynen, SA, 2019) |
| "Whether or not the use of metformin decreases the risk of gastric adenocarcinoma is unclear." | 3.91 | Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH; Zheng, J, 2019) |
| "We evaluated aspirin and non-aspirin NSAID use and risk of pancreatic adenocarcinoma in 141,940 participants from the Health Professionals Follow-up Study and Nurses' Health Study using multivariable-adjusted Cox proportional hazards regression." | 3.88 | Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. ( Babic, A; Cao, Y; Chan, AT; Clish, CB; Cochrane, BB; Fuchs, CS; Giovannucci, E; Hamada, T; Khalaf, N; Kraft, P; Manson, JE; Morales-Oyarvide, V; Ng, K; Ogino, S; Stampfer, M; Wolpin, BM; Yuan, C, 2018) |
| "A growing body of evidence indicates that use of low-dose aspirin (LDA) reduces the risk of certain adenocarcinomas." | 3.83 | Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. ( Cancian, M; Cricelli, C; Cricelli, I; Lapi, F; Levi, M; Parretti, D; Simonetti, M; Sobrero, A, 2016) |
| "Meta-analyses have demonstrated that low-dose aspirin reduces the risk of developing adenocarcinoma metastasis, and when colon cancer is detected during aspirin treatment, there is a remarkable 83% reduction in risk of metastasis." | 3.83 | Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis. ( Adler, D; Amin, T; Boutaud, O; Crews, BC; Harris, BK; Hoeksema, M; Hwang, HS; Knollmann, BC; Lammers, PE; Marnett, LJ; Massion, PP; Milne, G; Oates, JA; Oram, D; Sosa, IR, 2016) |
| "Aspirin use reduces colorectal cancer risk." | 3.83 | Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. ( Cao, Y; Chan, AT; Drew, DA; Fuchs, CS; Garrett, WS; Giovannucci, EL; Inamura, K; Lochhead, P; Mima, K; Morikawa, T; Nishihara, R; Nosho, K; Nowak, JA; Ogino, S; Qian, ZR; Song, M; Wang, M; Wu, K; Zhang, X, 2016) |
| "Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), low-dose aspirin and statins may decrease the risk of oesophageal adenocarcinoma (OAC) among patients with Barrett's oesophagus (BO)." | 3.81 | NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. ( Coloma, PM; Kuipers, EJ; Masclee, GM; Spaander, MC; Sturkenboom, MC, 2015) |
| "An estimated 335 colorectal cancers, 22 oesophageal adenocarcinomas and 29 oesophageal squamous cell carcinomas (SCC) were potentially prevented due to daily aspirin use." | 3.81 | Cancers prevented in Australia in 2010 through the consumption of aspirin. ( Bain, CJ; Green, AC; Jordan, SJ; Kendall, BJ; Nagle, CM; Neale, RE; Whiteman, DC; Wilson, LF, 2015) |
| "Data suggest that aspirin, statins, or a combination of the two drugs may lower the progression of Barrett's esophagus to esophageal adenocarcinoma." | 3.80 | Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. ( Choi, SE; Hur, C; Kong, CY; Perzan, KE; Tramontano, AC, 2014) |
| "Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus." | 3.80 | Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014) |
| "From the Swedish Cancer Register, we identified patients diagnosed with colorectal, lung, prostate and breast cancers between 2006 and 2009 and matched them to the Swedish Prescribed Drug Register to obtain information on low-dose aspirin use prior to diagnosis." | 3.79 | Low-dose aspirin use and cancer characteristics: a population-based cohort study. ( Czene, K; Jonsson, F; Lundholm, C; Pawitan, Y; Smedby, KE; Yin, L, 2013) |
| "Both aspirin and non-aspirin NSAID use reduced colorectal cancer risk (HR for users compared with non-users=0." | 3.77 | Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. ( Cross, AJ; Graubard, BI; Hollenbeck, AR; Laiyemo, AO; Ruder, EH; Schatzkin, A, 2011) |
| "To investigate the inhibitory effect of arsenic trioxide, aspirin and their combination on the growth of human gastric adenocarcinoma SGC-7901 graft in nude mice." | 3.75 | [Effect of arsenic trioxide combined with aspirin on the growth of human gastric adenocarcinoma graft in nude mice]. ( Liu, H; Qiu, J; Wu, YP, 2009) |
| ": To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments." | 3.75 | Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. ( Hongwei, L; Shu, L; Xiaoxin, M; Yanxia, L; Yingnan, J; Yuanqi, H, 2009) |
| "Although evidence suggests that aspirin and celecoxib may reduce the risk of esophageal adenocarcinoma (EAC) in patients with Barrett's esophagus (BE), these drugs can also cause harmful side effects." | 3.74 | Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus. ( Broughton, DE; Gazelle, GS; Hur, C; Nishioka, NS; Ozanne, E; Yachimski, P, 2008) |
| "Human esophageal adenocarcinoma cells were treated 18 hours with 50-300 muM deoxycholic acid, chenodeoxycholic acid, or taurocholic acid." | 3.74 | Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells. ( Geng, J; Gong, J; Song, Y; Wu, J, 2008) |
| " This study explored the effect of the NO-donating aspirin derivative, NCX 4040, on three human pancreatic adenocarcinoma cell lines (Capan-2, MIA PaCa-2 and T3M4)." | 3.73 | Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. ( Amadori, D; Bolla, M; Brigliadori, G; Fabbri, F; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W, 2006) |
| "We investigated the primary adenoma cells and HT-29 cells in an attempt to know whether NaBT and two NSAIDs (aspirin and NS-398) could be used as effective adjuvant for reducing cell proliferation, and to explore the possible mechanisms therein involved." | 3.72 | [Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2003) |
| " We assessed the cytotoxic activity of a new aspirin derivative, NCX 4016, after different exposure schedules, in three human colon adenocarcinoma cell lines." | 3.72 | NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines. ( Amadori, D; Medri, L; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W, 2003) |
| "Adenocarcinoma cells HT-29 were used to investigate whether butyrates and non-steroidal anti-inflammatory agents (NSAIDs, aspirin and NS-398) would be effective adjuvants for inducing apoptosis and to probe its possible mechanisms." | 3.71 | [The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells]. ( Gan, H; Ouyang, Q; Zhang, Z, 2002) |
| " Epidemiologic and experimental studies suggest that regular use of aspirin may reduce colorectal cancer risk." | 3.70 | Aspirin use and p53 expression in colorectal cancer. ( Asirwatham, JE; Caporaso, NE; Freedman, AN; Marshall, JR; Mettlin, CJ; Michalek, AM; Petrelli, NJ; Weiss, HA; Zhang, ZF, 1998) |
| "The Apc1638N mouse model, which carries a targeted mutant allele within the adenomatous polyposis (Apc) gene and develops intestinal tumours spontaneously, predominantly in the small bowel, was used to investigate the effects of two potential chemopreventive agents, aspirin and alpha-amylase resistant starch (RS)." | 3.70 | Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. ( Burn, J; Coaker, J; Fodde, R; Kartheuser, A; Kooshkghazi, MD; Mathers, JC; Williamson, SL, 1999) |
| " We evaluated the effect of aspirin (ASA) and three other structurally unrelated NSAIDs (indomethacin, naproxen, and piroxicam) on cell proliferation, cell cycle phase distribution, and the development of apoptosis in HT-29 colon adenocarcinoma cells in vitro." | 3.69 | Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. ( Koutsos, MI; Qiao, L; Rigas, B; Shiff, SJ, 1996) |
| "Our objective was to study the relationship between dispensed aspirin, nonaspirin nonsteroidal antiinflammatory drugs (NSAIDs), steroidal antiinflammatory drugs (SAIDs), acetaminophen, calcium, psyllium, and multivitamin preparations and the risk for subsequent colorectal adenoma and adenocarcinoma." | 3.69 | Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. ( Clark, WS; Cotsonis, GA; Lubin, MF; Peleg, II; Wilcox, CM, 1996) |
| "Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin." | 2.72 | Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021) |
| "Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin." | 2.53 | Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016) |
| "Men receiving radiation for prostate cancer frequently want to know what steps they can take to optimize their chance of cure and reduce their risk of side effects." | 2.49 | How can I help myself? A critical review of modifiable behaviors, medications, and complementary alternative medicine for men receiving radiotherapy for prostate cancer. ( Martin, NE; Tseng, YD, 2013) |
| "Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas." | 2.47 | Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011) |
| "Risk of lung cancer was a non-significant 16% lower for regular aspirin users of one or two tablets per week and a significant 55% higher for users of 15 or more tablets per week compared with women who never regularly used aspirin." | 2.44 | Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. ( Bain, C; Chan, AT; Colditz, GA; Feskanich, D; Pandeya, N; Speizer, FE, 2007) |
| "In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis." | 2.43 | [Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005) |
| "Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent." | 1.91 | In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023) |
| "The association of oesophageal cancer with drug use and clinical factors was evaluated." | 1.72 | Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study. ( Arai, J; Arai, M; Hasatani, K; Hayakawa, Y; Honda, T; Ikeya, T; Kawahara, T; Kawai, T; Kiyotoki, S; Koike, K; Niikura, R; Nishida, T; Sumiyoshi, T; Suzuki, N; Tsuji, Y; Yamada, A; Yoshida, N, 2022) |
| "Barrett esophagus is a premalignant change of the esophagus; however, malignant transformation to esophageal adenocarcinoma is rare in patients without dysplasia." | 1.72 | Barrett Esophagus: Rapid Evidence Review. ( Bryce, C; Bucaj, M; Gazda, R, 2022) |
| "Oesophageal adenocarcinoma is characterised by a strong male predominance." | 1.72 | Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study. ( Lagergren, J; Santoni, G; Xie, SH, 2022) |
| "Current available therapies for pancreatic ductal adenocarcinoma (PDAC) provide minimal overall survival benefits and cause severe adverse effects." | 1.62 | Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity. ( Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK, 2021) |
| " Thus, we assessed the efficacy associated with different dosing regimens of aspirin and naproxen." | 1.51 | Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma. ( Biddick, L; Janakiram, NB; Li, Q; Lightfoot, S; Lubet, RA; Madka, V; Miller, MS; Mohammed, A; Rao, CV; Sei, S; Singh, A; Steele, VE; Suen, CS; Zhang, Y, 2019) |
| "Follow-up started 1 year after prostate cancer diagnosis." | 1.51 | Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. ( Borre, M; Brasso, K; Dalton, SO; Dehlendorff, C; Friis, S; Hallas, J; Larsen, SB; Nørgaard, M; Pottegård, A; Skriver, C; Sørensen, HT, 2019) |
| "Acetaminophen use was not associated with the risk of cervical cancer." | 1.42 | Aspirin and Acetaminophen Use and the Risk of Cervical Cancer. ( Cannioto, RA; Friel, G; Hampras, SS; Kolomeyevskaya, NV; Kruszka, B; Lele, SB; Liu, CS; Moysich, KB; Odunsi, KO; Schmitt, K, 2015) |
| "He had been treated for lung cancer by chemotherapy and irradiation 3 years earlier." | 1.40 | [Case of cardiac tamponade during the treatment of acute cerebral infarction]. ( Nagasawa, H; Ono, H; Tanaka, H; Yamakawa, T, 2014) |
| "Pancreatic cancer is a deadly disease killing 37,000 Americans each year." | 1.39 | A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. ( Grandhi, BK; Prabhu, S; Thakkar, A; Wang, J, 2013) |
| "Aspirin (ASA) is a non-selective cyclooxygenase (COX) inhibitor that contributes to the treatment of inflammatory conditions such as RA." | 1.39 | Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells. ( Chang, HY; Chang, PY; Chen, TL; Cheng, AL; Chuang, SE; Hsieh, MC; Lai, GM; Lee, LM; Yan, KH; Yan, MD; Yao, CJ, 2013) |
| "Patients who underwent ESD for early gastric neoplasms at the National Cancer Center Hospital, Korea, between November 2008 and January 2011 were enrolled." | 1.38 | Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms. ( Cho, SJ; Choi, IJ; Kim, CG; Kim, HJ; Kim, YW; Kwak, MH; Lee, JH; Lee, JY; Nam, BH; Ryu, KW, 2012) |
| " Further study is needed to confirm these findings and to determine the optimal dosing and schedule, as well as the relative benefits and risks, of both therapies in combination with RT." | 1.38 | Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. ( Buyyounouski, MK; Horwitz, EM; Li, T; Zaorsky, NG, 2012) |
| "The risk of prostate cancer-specific mortality (PCSM) was compared between the AC and non-AC groups." | 1.38 | Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. ( Carroll, PR; Chan, JM; Choe, KS; Cowan, JE; D'Amico, AV; Liauw, SL, 2012) |
| "The purpose of this work was to assess synergistic inhibitory responses of a novel chemopreventive combination regimen of drugs namely, aspirin in combination with calcium and folic acid on two human colon cancer cell lines, HT-29 and SW-480." | 1.36 | Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer. ( Chaudhary, A; Kanthamneni, N; Prabhu, S; Wang, J, 2010) |
| "Hemorrhagic cholecystitis is a rare and potentially fatal complication of biliary tract disease." | 1.36 | Hemorrhagic cholecystitis after anticoagulation therapy. ( Chen, CL; Chen, YY; Hsu, YH; Huang, SC; Yi, CH, 2010) |
| "Baby aspirin and NSAID use was associated with a significant reduction in risk of NSCLC only among 65- to 74-year-olds." | 1.35 | Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. ( Claeys, GB; Cote, ML; Prysak, G; Schwartz, AG; Van Dyke, AL; Wenzlaff, AS, 2008) |
| "examined Barrett's esophagus patient preferences for cancer chemoprevention with either aspirin or celecoxib." | 1.35 | Chemoprevention and Barrett's esophagus: decisions, decisions. ( Falk, GW; Jankowski, J, 2008) |
| " We assessed the presence of duration-response and dose-response effects." | 1.34 | Chronic proton pump inhibitor therapy and the risk of colorectal cancer. ( Hennessy, S; Hwang, WT; Lewis, JD; Propert, K; Sedarat, A; Yang, YX, 2007) |
| "5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells." | 1.33 | Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005) |
| "In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal adenocarcinoma and 260 population controls were recruited." | 1.33 | Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. ( Anderson, LA; Comber, H; Ferguson, HR; Johnston, BT; McGuigan, J; Murphy, SJ; Murray, LJ; Reynolds, JV; Watson, RG, 2006) |
| "Aspirin has been shown to be associated with reduced risk of developing colorectal carcinoma and other cancers." | 1.33 | Regular aspirin use and esophageal cancer risk. ( Baker, JA; Javle, MM; Jayaprakash, V; McCann, SE; Menezes, RJ; Moysich, KB; Natarajan, N; Reid, ME, 2006) |
| "NO-ASA inhibits colon cancer cell growth several hundred times more potently than does ASA." | 1.33 | Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. ( Gao, J; Liu, X; Rigas, B, 2005) |
| "The aspirin effects were apparently unrelated to prostaglandin biosynthesis inhibition, since although these cells were found to express high levels of cyclooxygenase 1 (COX-1) and low levels of COX-2 proteins, they did not produce any measurable net amounts of prostaglandins, based on both utilization of radiolabelled arachidonic acid and the radioimmunoassay of prostaglandins E2 and F2 alpha." | 1.32 | Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells. ( Andriamihaja, M; Blachier, F; Camous, S; Charpigny, G; Eklou-Kalonji, E; Mayeur, C; Reinaud, P; Robert, V, 2003) |
| "Aspirin could inhibit the AP-1 binding activation stimulated by fetal calf serum." | 1.32 | [Inhibition effect of aspirin on the growth of gastric cancer and the mechanism there-in involved]. ( Tang, C; Wang, C, 2003) |
| "Ibuprofen was significantly more effective against human prostate cancer cells in vitro than the other tested nonprescription NSAIDs." | 1.31 | Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. ( Andrews, J; Andrews, P; Djakiew, D; Krygier, S, 2002) |
| "Aspirin has also been shown to inhibit cell proliferation in human tumor cell lines and to induce apoptosis in colonic mucosa of familial polyposis patients." | 1.30 | Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells. ( Acquaviva, AM; Apicella, A; Di Popolo, A; Memoli, A; Pignata, S; Ricchi, P; Zarrilli, R, 1997) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "A case-control study of stomach cancer which includes 448 cases and 610 hospital controls has been conducted in Moscow, Russia." | 1.30 | Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. ( Borisova, E; Chkhikvadze, V; Maximovitch, D; Zaridze, D, 1999) |
| "We have observed that in human colon cancer the expression of HLA class I and II antigens is reduced or lost; loss of HLA antigens is suspected to be a mechanism by which the malignant cell escapes the immune surveillance." | 1.29 | Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. ( Arvind, P; Duceman, B; Lovelace, CI; Papavassiliou, ED; Qiao, L; Rigas, B; Tsioulias, GJ, 1995) |
| " These occurred only in the groups given MNNG in combination with stress, aspirin, or sodium taurocholate, and did not occur in experimental groups given either MNNG, stress, aspirin, or sodium taurocholate alone, and did not occur in the control group." | 1.27 | Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N'-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. ( Cohen, A; Geller, SA; Horowitz, I; Toth, LS; Werther, JL, 1984) |
| " A prevention of thromboembolic disease by individual dosage of heparin must be considered in patients at high risk for thromboembolic disease." | 1.27 | [Mortality and morbidity of thromboembolism in drug prevention--5-year analysis]. ( Hopp, A; Hopp, H; Knispel, J, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (9.93) | 18.7374 |
| 1990's | 20 (13.25) | 18.2507 |
| 2000's | 46 (30.46) | 29.6817 |
| 2010's | 57 (37.75) | 24.3611 |
| 2020's | 13 (8.61) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, SH | 3 |
| Santoni, G | 2 |
| Lagergren, J | 4 |
| Arai, J | 1 |
| Niikura, R | 1 |
| Hayakawa, Y | 1 |
| Kawahara, T | 1 |
| Honda, T | 1 |
| Hasatani, K | 1 |
| Yoshida, N | 1 |
| Nishida, T | 1 |
| Sumiyoshi, T | 1 |
| Kiyotoki, S | 1 |
| Ikeya, T | 1 |
| Arai, M | 2 |
| Suzuki, N | 1 |
| Tsuji, Y | 1 |
| Yamada, A | 1 |
| Kawai, T | 1 |
| Koike, K | 1 |
| Kwon, S | 1 |
| Ma, W | 2 |
| Drew, DA | 2 |
| Klempner, SJ | 1 |
| Leonardo, BM | 1 |
| Flynn, JJ | 1 |
| Cao, Y | 3 |
| Giovannucci, EL | 2 |
| Bao, Y | 1 |
| Fuchs, CS | 3 |
| Song, M | 2 |
| Chan, AT | 5 |
| Holmberg, D | 1 |
| Kauppila, JH | 1 |
| Mattsson, F | 1 |
| Asplund, J | 1 |
| Leijonmarck, W | 1 |
| Lai, SW | 1 |
| Hwang, BF | 1 |
| Liu, CS | 2 |
| Liao, KF | 1 |
| Bryce, C | 1 |
| Bucaj, M | 1 |
| Gazda, R | 1 |
| Acuna, N | 1 |
| Park, SY | 1 |
| Le Marchand, L | 1 |
| Hébert, JR | 1 |
| Boushey, C | 1 |
| Wilkens, LR | 2 |
| Wu, AH | 1 |
| Setiawan, VW | 1 |
| Susan, M | 1 |
| Macasoi, I | 1 |
| Pinzaru, I | 1 |
| Dehelean, C | 1 |
| Ilia, I | 1 |
| Susan, R | 1 |
| Ionita, I | 1 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Madka, V | 1 |
| Zhang, Y | 1 |
| Singh, A | 1 |
| Biddick, L | 1 |
| Li, Q | 1 |
| Lightfoot, S | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Suen, CS | 1 |
| Miller, MS | 1 |
| Sei, S | 1 |
| Rao, CV | 2 |
| Zheng, J | 1 |
| Zhang, T | 1 |
| Wang, Q | 1 |
| Ma, WY | 1 |
| Wang, K | 2 |
| Chang, X | 1 |
| Johnson, ML | 1 |
| Bai, R | 1 |
| Bode, AM | 1 |
| Foster, NR | 1 |
| Falk, GW | 2 |
| Limburg, PJ | 1 |
| Iyer, PG | 1 |
| Dong, Z | 1 |
| Moayyedi, P | 2 |
| El-Serag, HB | 2 |
| Arango-Varela, SS | 1 |
| Luzardo-Ocampo, I | 1 |
| Reyes-Dieck, C | 1 |
| Yahia, EM | 1 |
| Maldonado-Celis, ME | 1 |
| Karelia, DN | 1 |
| Kim, S | 1 |
| K Pandey, M | 1 |
| Plano, D | 1 |
| Amin, S | 1 |
| Lu, J | 1 |
| Sharma, AK | 1 |
| Zhao, Z | 1 |
| Yin, Z | 2 |
| Zhang, C | 1 |
| Brusselaers, N | 1 |
| Wahlin, K | 1 |
| Engstrand, L | 1 |
| Khalaf, N | 1 |
| Yuan, C | 1 |
| Hamada, T | 1 |
| Babic, A | 1 |
| Morales-Oyarvide, V | 1 |
| Kraft, P | 1 |
| Ng, K | 1 |
| Giovannucci, E | 1 |
| Ogino, S | 2 |
| Stampfer, M | 1 |
| Cochrane, BB | 1 |
| Manson, JE | 1 |
| Clish, CB | 1 |
| Wolpin, BM | 1 |
| Hvid-Jensen, F | 1 |
| Drewes, AM | 1 |
| Skriver, C | 1 |
| Dehlendorff, C | 1 |
| Borre, M | 1 |
| Brasso, K | 1 |
| Larsen, SB | 1 |
| Dalton, SO | 1 |
| Nørgaard, M | 1 |
| Pottegård, A | 1 |
| Hallas, J | 1 |
| Sørensen, HT | 1 |
| Friis, S | 1 |
| Väyrynen, JP | 1 |
| Väyrynen, SA | 1 |
| Sirniö, P | 1 |
| Minkkinen, I | 1 |
| Klintrup, K | 1 |
| Karhu, T | 1 |
| Mäkelä, J | 1 |
| Herzig, KH | 1 |
| Karttunen, TJ | 1 |
| Tuomisto, A | 1 |
| Mäkinen, MJ | 1 |
| Bonaterra, GA | 1 |
| Kelber, O | 1 |
| Weiser, D | 1 |
| Kinscherf, R | 1 |
| Tseng, YD | 1 |
| Martin, NE | 1 |
| Yan, KH | 1 |
| Lee, LM | 1 |
| Hsieh, MC | 1 |
| Yan, MD | 1 |
| Yao, CJ | 1 |
| Chang, PY | 1 |
| Chen, TL | 1 |
| Chang, HY | 1 |
| Cheng, AL | 1 |
| Lai, GM | 1 |
| Chuang, SE | 1 |
| Jonsson, F | 1 |
| Yin, L | 1 |
| Lundholm, C | 1 |
| Smedby, KE | 1 |
| Czene, K | 1 |
| Pawitan, Y | 1 |
| Colussi, D | 1 |
| Brandi, G | 1 |
| Bazzoli, F | 1 |
| Ricciardiello, L | 1 |
| Grandhi, BK | 1 |
| Thakkar, A | 1 |
| Wang, J | 2 |
| Prabhu, S | 2 |
| Choi, SE | 1 |
| Perzan, KE | 1 |
| Tramontano, AC | 1 |
| Kong, CY | 2 |
| Hur, C | 3 |
| Xiaohua, Y | 1 |
| Zhenjiang, Y | 1 |
| Weidong, L | 1 |
| Pengcheng, X | 1 |
| Sidong, C | 1 |
| Ishikawa, H | 1 |
| Mutoh, M | 1 |
| Suzuki, S | 1 |
| Tokudome, S | 1 |
| Saida, Y | 1 |
| Abe, T | 1 |
| Okamura, S | 1 |
| Tajika, M | 1 |
| Joh, T | 1 |
| Tanaka, S | 1 |
| Kudo, SE | 1 |
| Matsuda, T | 1 |
| Iimuro, M | 1 |
| Yukawa, T | 1 |
| Takayama, T | 1 |
| Sato, Y | 1 |
| Lee, K | 1 |
| Kitamura, S | 1 |
| Mizuno, M | 1 |
| Sano, Y | 1 |
| Gondo, N | 1 |
| Sugimoto, K | 1 |
| Kusunoki, M | 1 |
| Goto, C | 1 |
| Matsuura, N | 1 |
| Sakai, T | 1 |
| Wakabayashi, K | 1 |
| Cowie, A | 1 |
| Noble, F | 1 |
| Underwood, T | 1 |
| Wang, R | 2 |
| Wang, Y | 1 |
| Gao, Z | 1 |
| Qu, X | 1 |
| Nagasawa, H | 1 |
| Ono, H | 1 |
| Tanaka, H | 1 |
| Yamakawa, T | 1 |
| Esquivias, P | 2 |
| Cebrián, C | 2 |
| Morandeira, A | 1 |
| Santander, S | 3 |
| Ortego, J | 1 |
| García-González, MA | 2 |
| Lanas, A | 2 |
| Piazuelo, E | 3 |
| Sung, JJ | 1 |
| Claudius, AK | 1 |
| Kankipati, CS | 1 |
| Kilari, RS | 1 |
| Hassan, S | 1 |
| Guest, K | 1 |
| Russell, ST | 1 |
| Perry, CJ | 1 |
| Stark, LA | 1 |
| Nicholl, ID | 1 |
| Li, P | 2 |
| Wu, H | 1 |
| Zhang, H | 1 |
| Shi, Y | 1 |
| Xu, J | 2 |
| Ye, Y | 1 |
| Xia, D | 1 |
| Yang, J | 1 |
| Cai, J | 1 |
| Wu, Y | 1 |
| Matsumura, T | 1 |
| Maruoka, D | 1 |
| Okimoto, K | 1 |
| Minemura, S | 1 |
| Ishigami, H | 1 |
| Saito, K | 1 |
| Nakagawa, T | 1 |
| Katsuno, T | 1 |
| Yokosuka, O | 1 |
| Masclee, GM | 1 |
| Coloma, PM | 1 |
| Spaander, MC | 1 |
| Kuipers, EJ | 1 |
| Sturkenboom, MC | 1 |
| Basudhar, D | 1 |
| Cheng, RC | 1 |
| Bharadwaj, G | 1 |
| Ridnour, LA | 1 |
| Wink, DA | 1 |
| Miranda, KM | 1 |
| Friel, G | 1 |
| Kolomeyevskaya, NV | 1 |
| Hampras, SS | 1 |
| Kruszka, B | 1 |
| Schmitt, K | 1 |
| Cannioto, RA | 1 |
| Lele, SB | 1 |
| Odunsi, KO | 1 |
| Moysich, KB | 2 |
| Maity, G | 1 |
| De, A | 1 |
| Das, A | 1 |
| Banerjee, S | 1 |
| Sarkar, S | 1 |
| Banerjee, SK | 1 |
| Wilson, LF | 1 |
| Green, AC | 3 |
| Kendall, BJ | 1 |
| Jordan, SJ | 1 |
| Nagle, CM | 1 |
| Bain, CJ | 2 |
| Neale, RE | 1 |
| Whiteman, DC | 4 |
| Lapi, F | 1 |
| Levi, M | 1 |
| Simonetti, M | 1 |
| Cancian, M | 1 |
| Parretti, D | 1 |
| Cricelli, I | 1 |
| Sobrero, A | 1 |
| Cricelli, C | 1 |
| Hardie, C | 1 |
| Jung, Y | 1 |
| Jameson, M | 1 |
| Matsuo, K | 1 |
| Cahoon, SS | 1 |
| Yoshihara, K | 1 |
| Shida, M | 1 |
| Kakuda, M | 1 |
| Adachi, S | 1 |
| Moeini, A | 1 |
| Machida, H | 1 |
| Garcia-Sayre, J | 1 |
| Ueda, Y | 1 |
| Enomoto, T | 1 |
| Mikami, M | 1 |
| Roman, LD | 1 |
| Sood, AK | 1 |
| Thrift, AP | 2 |
| De Martino, A | 1 |
| Conde, B | 1 |
| Emperador, S | 1 |
| Carrera-Lasfuentes, P | 1 |
| Nishihara, R | 1 |
| Qian, ZR | 1 |
| Mima, K | 1 |
| Inamura, K | 1 |
| Nowak, JA | 1 |
| Lochhead, P | 1 |
| Nosho, K | 1 |
| Morikawa, T | 1 |
| Zhang, X | 1 |
| Wu, K | 1 |
| Wang, M | 1 |
| Garrett, WS | 1 |
| Boutaud, O | 1 |
| Sosa, IR | 1 |
| Amin, T | 1 |
| Oram, D | 1 |
| Adler, D | 1 |
| Hwang, HS | 1 |
| Crews, BC | 1 |
| Milne, G | 1 |
| Harris, BK | 1 |
| Hoeksema, M | 1 |
| Knollmann, BC | 1 |
| Lammers, PE | 1 |
| Marnett, LJ | 1 |
| Massion, PP | 1 |
| Oates, JA | 1 |
| Anderson, LA | 2 |
| Murray, LJ | 2 |
| Cook, MB | 1 |
| Shaheen, NJ | 2 |
| Rubenstein, JH | 1 |
| Vaughan, TL | 2 |
| Schneider, JL | 1 |
| Corley, DA | 2 |
| Leung, AM | 1 |
| Redlak, MJ | 2 |
| Miller, TA | 2 |
| Jankowski, J | 3 |
| Broughton, DE | 1 |
| Ozanne, E | 1 |
| Yachimski, P | 1 |
| Nishioka, NS | 1 |
| Gazelle, GS | 2 |
| Wu, J | 1 |
| Gong, J | 1 |
| Geng, J | 1 |
| Song, Y | 1 |
| Bazuro, GE | 1 |
| Torino, F | 1 |
| Gasparini, G | 1 |
| Capurso, L | 1 |
| Liu, JF | 1 |
| Jamieson, GG | 1 |
| Wu, TC | 1 |
| Zhu, GJ | 1 |
| Drew, PA | 1 |
| Epplein, M | 1 |
| Nomura, AM | 1 |
| Henderson, BE | 1 |
| Kolonel, LN | 1 |
| Gatenby, PA | 1 |
| Ramus, JR | 1 |
| Caygill, CP | 1 |
| Winslet, MC | 1 |
| Watson, A | 1 |
| Qiu, J | 1 |
| Wu, YP | 1 |
| Liu, H | 1 |
| Xiaoxin, M | 1 |
| Yingnan, J | 1 |
| Yanxia, L | 1 |
| Shu, L | 1 |
| Yuanqi, H | 1 |
| Hongwei, L | 1 |
| Pandeya, N | 3 |
| Webb, PM | 2 |
| Sadeghi, S | 2 |
| Hayeck, TJ | 1 |
| Yeh, JM | 1 |
| Richards, EM | 1 |
| Richards, EB | 1 |
| Spechler, SJ | 1 |
| Kanthamneni, N | 1 |
| Chaudhary, A | 1 |
| Chen, YY | 1 |
| Yi, CH | 1 |
| Chen, CL | 1 |
| Huang, SC | 1 |
| Hsu, YH | 1 |
| Rizvi, S | 1 |
| Demars, CJ | 1 |
| Comba, A | 1 |
| Gainullin, VG | 1 |
| Rizvi, Z | 1 |
| Almada, LL | 1 |
| Lomberk, G | 1 |
| Fernández-Zapico, ME | 1 |
| Buttar, NS | 1 |
| Jankowski, JA | 1 |
| Hooper, PA | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Wang, F | 1 |
| Lv, ZS | 1 |
| Fu, YK | 1 |
| Scholl, S | 1 |
| Dellon, ES | 1 |
| Ruder, EH | 1 |
| Laiyemo, AO | 1 |
| Graubard, BI | 1 |
| Hollenbeck, AR | 1 |
| Schatzkin, A | 1 |
| Cross, AJ | 1 |
| Gao, W | 1 |
| Liu, L | 1 |
| Huang, P | 1 |
| Yin, Y | 1 |
| Liu, P | 1 |
| Yu, R | 1 |
| Shu, Y | 1 |
| Nicholson, A | 1 |
| Antonoff, MB | 1 |
| D'Cunha, J | 1 |
| Cho, SJ | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Lee, JY | 1 |
| Nam, BH | 1 |
| Kwak, MH | 1 |
| Kim, HJ | 1 |
| Ryu, KW | 1 |
| Lee, JH | 1 |
| Kim, YW | 1 |
| Rothwell, PM | 1 |
| Wilson, M | 1 |
| Price, JF | 1 |
| Belch, JF | 1 |
| Meade, TW | 1 |
| Mehta, Z | 1 |
| Beales, IL | 1 |
| Vardi, I | 1 |
| Dearman, L | 1 |
| Zaorsky, NG | 1 |
| Buyyounouski, MK | 1 |
| Li, T | 1 |
| Horwitz, EM | 1 |
| Choe, KS | 1 |
| Cowan, JE | 1 |
| Chan, JM | 1 |
| Carroll, PR | 1 |
| D'Amico, AV | 1 |
| Liauw, SL | 1 |
| Pennarun, B | 1 |
| Kleibeuker, JH | 1 |
| Boersma-van Ek, W | 1 |
| Kruyt, FA | 1 |
| Hollema, H | 1 |
| de Vries, EG | 1 |
| de Jong, S | 1 |
| Andrews, J | 1 |
| Djakiew, D | 1 |
| Krygier, S | 1 |
| Andrews, P | 1 |
| Kerlikowske, K | 1 |
| Verma, R | 1 |
| Buffler, P | 1 |
| Brown, JR | 1 |
| Seed, MP | 1 |
| Willoughby, DA | 1 |
| Tesei, A | 2 |
| Ricotti, L | 1 |
| Ulivi, P | 2 |
| Medri, L | 1 |
| Amadori, D | 2 |
| Zoli, W | 2 |
| Eklou-Kalonji, E | 1 |
| Andriamihaja, M | 1 |
| Reinaud, P | 1 |
| Mayeur, C | 1 |
| Camous, S | 1 |
| Robert, V | 1 |
| Charpigny, G | 1 |
| Blachier, F | 1 |
| Wang, C | 1 |
| Tang, C | 1 |
| Zhang, Z | 2 |
| Ouyang, Q | 2 |
| Gan, H | 2 |
| Scherübl, H | 1 |
| Sutter, AP | 1 |
| Zeitz, M | 1 |
| Montalto, M | 1 |
| Maggiano, N | 1 |
| Ricci, R | 1 |
| Curigliano, V | 1 |
| Santoro, L | 1 |
| Di Nicuolo, F | 1 |
| Vecchio, FM | 1 |
| Gasbarrini, A | 1 |
| Gasbarrini, G | 1 |
| Sclabas, GM | 1 |
| Uwagawa, T | 1 |
| Schmidt, C | 1 |
| Hess, KR | 1 |
| Evans, DB | 1 |
| Abbruzzese, JL | 1 |
| Chiao, PJ | 1 |
| Ashktorab, H | 1 |
| Dawkins, FW | 1 |
| Mohamed, R | 1 |
| Larbi, D | 1 |
| Smoot, DT | 1 |
| Kinoshita, Y | 1 |
| Yuki, T | 1 |
| Spiegel, A | 1 |
| Hundley, TR | 1 |
| Chen, J | 1 |
| Gao, J | 3 |
| Ouyang, N | 2 |
| Liu, X | 4 |
| Go, MF | 1 |
| Tsioulias, GJ | 2 |
| Kashfi, K | 2 |
| Rigas, B | 7 |
| He, H | 1 |
| Xia, HH | 1 |
| Wang, JD | 1 |
| Gu, Q | 1 |
| Lin, MC | 1 |
| Zou, B | 1 |
| Lam, SK | 1 |
| Chan, AO | 1 |
| Yuen, MF | 1 |
| Kung, HF | 1 |
| Wong, BC | 1 |
| Jayaprakash, V | 1 |
| Menezes, RJ | 1 |
| Javle, MM | 1 |
| McCann, SE | 1 |
| Baker, JA | 1 |
| Reid, ME | 1 |
| Natarajan, N | 1 |
| Johnston, BT | 1 |
| Watson, RG | 1 |
| Murphy, SJ | 1 |
| Ferguson, HR | 1 |
| Comber, H | 1 |
| McGuigan, J | 1 |
| Reynolds, JV | 1 |
| Rosetti, M | 1 |
| Fabbri, F | 1 |
| Vannini, I | 1 |
| Brigliadori, G | 1 |
| Bolla, M | 1 |
| Konturek, PC | 1 |
| Kania, J | 1 |
| Burnat, G | 1 |
| Hahn, EG | 1 |
| Power, JJ | 1 |
| Yang, YX | 1 |
| Hennessy, S | 1 |
| Propert, K | 1 |
| Hwang, WT | 1 |
| Sedarat, A | 1 |
| Lewis, JD | 1 |
| Jiménez, P | 1 |
| García, A | 1 |
| Feskanich, D | 1 |
| Bain, C | 1 |
| Speizer, FE | 1 |
| Colditz, GA | 1 |
| Williams, JL | 2 |
| Ji, P | 1 |
| Van Dyke, AL | 1 |
| Cote, ML | 1 |
| Prysak, G | 1 |
| Claeys, GB | 1 |
| Wenzlaff, AS | 1 |
| Schwartz, AG | 1 |
| Accioly, MT | 1 |
| Pacheco, P | 1 |
| Maya-Monteiro, CM | 1 |
| Carrossini, N | 1 |
| Robbs, BK | 1 |
| Oliveira, SS | 1 |
| Kaufmann, C | 1 |
| Morgado-Diaz, JA | 1 |
| Bozza, PT | 1 |
| Viola, JP | 1 |
| Takahashi, M | 1 |
| Kokubo, T | 1 |
| Furukawa, F | 1 |
| Kurokawa, Y | 1 |
| Hayashi, Y | 1 |
| Chang, TH | 1 |
| Lee, YC | 1 |
| Lee, KY | 1 |
| Sun, CH | 1 |
| Chang, YP | 1 |
| Cohen, A | 1 |
| Geller, SA | 1 |
| Horowitz, I | 1 |
| Toth, LS | 1 |
| Werther, JL | 1 |
| Hara, Y | 1 |
| Steiner, M | 1 |
| Baldini, MG | 1 |
| Sato, K | 1 |
| Mori, Y | 1 |
| Okamura, N | 1 |
| Mizuuchi, H | 1 |
| Arvind, P | 1 |
| Papavassiliou, ED | 1 |
| Qiao, L | 2 |
| Lovelace, CI | 1 |
| Duceman, B | 1 |
| Reddy, BS | 1 |
| Rivenson, A | 1 |
| Kelloff, G | 1 |
| Shiff, SJ | 1 |
| Koutsos, MI | 1 |
| Peters, FP | 1 |
| Doevendans, PA | 1 |
| Erdkamp, FL | 1 |
| Van Der Ent, FW | 1 |
| De Heer, F | 1 |
| Peleg, II | 1 |
| Lubin, MF | 1 |
| Cotsonis, GA | 1 |
| Clark, WS | 1 |
| Wilcox, CM | 1 |
| Sandler, RS | 1 |
| Clària, J | 1 |
| Lee, MH | 1 |
| Serhan, CN | 1 |
| Folwaczny, C | 1 |
| Lorenz, R | 1 |
| Loeschke, K | 1 |
| Williams, CS | 1 |
| Smalley, W | 1 |
| DuBois, RN | 1 |
| Ricchi, P | 1 |
| Pignata, S | 1 |
| Di Popolo, A | 1 |
| Memoli, A | 1 |
| Apicella, A | 1 |
| Zarrilli, R | 1 |
| Acquaviva, AM | 1 |
| Farrow, DC | 1 |
| Hansten, PD | 1 |
| Stanford, JL | 1 |
| Risch, HA | 1 |
| Gammon, MD | 1 |
| Chow, WH | 1 |
| Dubrow, R | 1 |
| Ahsan, H | 1 |
| Mayne, ST | 1 |
| Schoenberg, JB | 1 |
| West, AB | 1 |
| Rotterdam, H | 1 |
| Fraumeni, JF | 1 |
| Blot, WJ | 1 |
| Sönksen, P | 1 |
| Jacobs, H | 1 |
| Orme, S | 1 |
| Belchetz, P | 1 |
| Morgan, G | 1 |
| Freedman, AN | 1 |
| Michalek, AM | 1 |
| Weiss, HA | 1 |
| Zhang, ZF | 1 |
| Marshall, JR | 1 |
| Mettlin, CJ | 1 |
| Asirwatham, JE | 1 |
| Petrelli, NJ | 1 |
| Caporaso, NE | 1 |
| Bak, AW | 1 |
| McKnight, W | 1 |
| Del Soldato, P | 1 |
| Calignano, A | 1 |
| Cirino, G | 1 |
| Wallace, JL | 1 |
| Bours, V | 1 |
| Jerusalem, G | 1 |
| Fillet, G | 1 |
| Schwenger, P | 1 |
| Alpert, D | 1 |
| Skolnik, EY | 1 |
| Vilcek, J | 1 |
| Williamson, SL | 1 |
| Kartheuser, A | 1 |
| Coaker, J | 1 |
| Kooshkghazi, MD | 1 |
| Fodde, R | 1 |
| Burn, J | 1 |
| Mathers, JC | 1 |
| Zaridze, D | 1 |
| Borisova, E | 1 |
| Maximovitch, D | 1 |
| Chkhikvadze, V | 1 |
| Shao, J | 1 |
| Fujiwara, T | 1 |
| Kadowaki, Y | 1 |
| Fukazawa, T | 1 |
| Waku, T | 1 |
| Itoshima, T | 1 |
| Yamatsuji, T | 1 |
| Nishizaki, M | 1 |
| Roth, JA | 1 |
| Tanaka, N | 1 |
| Weddle, DL | 1 |
| Tithoff, P | 1 |
| Williams, M | 1 |
| Schuller, HM | 1 |
| Akre, K | 1 |
| Ekström, AM | 1 |
| Signorello, LB | 1 |
| Hansson, LE | 1 |
| Nyrén, O | 1 |
| Borgo, S | 1 |
| Hasan, I | 1 |
| Castillo, E | 1 |
| Traganos, F | 1 |
| Karna, E | 1 |
| Pałka, JA | 1 |
| Rao, GA | 1 |
| Abraham, S | 1 |
| Pollard, M | 1 |
| Chang, CF | 1 |
| Luckert, PH | 1 |
| Wald, A | 1 |
| Milligan, FD | 1 |
| Bastida, E | 1 |
| Almirall, L | 1 |
| Ordinas, A | 1 |
| Hopp, H | 1 |
| Hopp, A | 1 |
| Knispel, J | 1 |
| Kolenich, JJ | 1 |
| Mansour, EG | 1 |
| Flynn, A | 1 |
| Gasic, GJ | 2 |
| Gasic, TB | 2 |
| Murphy, S | 2 |
| Lightdale, CJ | 1 |
| Kurtz, RC | 1 |
| Boyle, CC | 1 |
| Sherlock, P | 1 |
| Winawer, SJ | 1 |
| Liu, T | 1 |
| Smith, GW | 1 |
| Rankin, JT | 1 |
| Galanti, N | 1 |
| Johnson, T | 1 |
| Moertel, CG | 1 |
| Ahmann, DL | 1 |
| Taylor, WF | 1 |
| Schwartau, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02602938] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-11-30 | Recruiting | ||
| A Prospective Study To Define The Role Of Various Factors In Development And Progression Of Gastroesophageal Reflux Disease (GERD) And Barrett's Esophagus And The Creation Of A Registry.[NCT00574327] | 3,000 participants (Anticipated) | Observational | 2006-01-31 | Recruiting | |||
| Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project[NCT00586404] | 1,250 participants (Actual) | Observational | 2007-11-30 | Terminated (stopped due to lack of enrollment) | |||
| A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma[NCT02748304] | 52 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to The enrollment of this study was slow. With the approval of lenvatinib in HCC,many patients choose the new drug, so subsequent enrollment may be more difficult.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for aspirin and Adenocarcinoma
| Article | Year |
|---|---|
Current Status of Chemoprevention in Barrett's Esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N | 2021 |
Lifestyle interventions can reduce the risk of Barrett's esophagus: a systematic review and meta-analysis of 62 studies involving 250,157 participants.
Topics: Adenocarcinoma; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Aspirin; B | 2021 |
How can I help myself? A critical review of modifiable behaviors, medications, and complementary alternative medicine for men receiving radiotherapy for prostate cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Complementary Therapies; Exercise; Health Behavio | 2013 |
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Aspirin; Chromosomal Instab | 2013 |
The non-linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose-response meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; | 2014 |
Strategies to improve outcomes in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi | 2014 |
Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Class I Phosphatid | 2015 |
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres | 2016 |
Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; ErbB Recepto | 2008 |
Chemoprevention in Barrett's esophagus: A pill a day?
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Diet; Esophagea | 2011 |
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2011 |
Meta-analysis on the association between nonsteroidal anti-inflammatory drug use and lung cancer risk.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Humans; Lung | 2012 |
Acid reflux and oesophageal cancer.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas | 2011 |
Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Drug Administration Schedule; Female; Humans; Incide | 2012 |
Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Dose-Res | 2003 |
[Medical treatment of Barrett's esophagus].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo | 2005 |
Prevention of cancer in the upper gastrointestinal tract with COX-inhibition. Still an option?
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cardiovascular Diseases; Cell Transformation, Neop | 2007 |
Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 2007 |
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-S | 1996 |
Aspirin use and potential mechanisms for colorectal cancer prevention.
Topics: Adenocarcinoma; Adenomatous Polyps; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Color | 1997 |
6 trials available for aspirin and Adenocarcinoma
| Article | Year |
|---|---|
Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Carcinogenesis; Cell Line, Tumor; Cell Prolifer | 2019 |
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Alcohol Drinking; Anticarcinogenic Agents; Aspirin; Colonic Ne | 2014 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C | 2009 |
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cohort Studies; Demography; Eso | 2009 |
The role of fiberoptic endoscopy in the diagnosis and management of duodenal neoplasms.
Topics: Adenocarcinoma; Adult; Aged; Aspirin; Cautery; Clinical Trials as Topic; Duodenal Neoplasms; Endosco | 1975 |
Aspirin and pancreatic cancer pain.
Topics: Adenocarcinoma; Aspirin; Carcinoma; Codeine; Colonic Neoplasms; Humans; Pancreatic Neoplasms; Placeb | 1971 |
125 other studies available for aspirin and Adenocarcinoma
| Article | Year |
|---|---|
Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Esophageal Neoplas | 2022 |
Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
Topics: Adenocarcinoma; Aspirin; Case-Control Studies; Chemoprevention; Esophageal Neoplasms; Esophageal Squ | 2022 |
Association Between Aspirin Use and Gastric Adenocarcinoma: A Prospective Cohort Study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Follow-Up Studies; Humans; | 2022 |
Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma.
Topics: Adenocarcinoma; Aspirin; Cohort Studies; Gastrectomy; Humans; Neoplasm Staging; Stomach Neoplasms | 2022 |
Aspirin Use and Gastric Adenocarcinoma-Letter.
Topics: Adenocarcinoma; Aspirin; Gastric Mucosa; Humans; Stomach Neoplasms | 2022 |
Aspirin Use and Gastric Adenocarcinoma-Reply.
Topics: Adenocarcinoma; Aspirin; Gastric Mucosa; Humans; Stomach Neoplasms | 2022 |
Barrett Esophagus: Rapid Evidence Review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Humans; | 2022 |
Diet quality and risk of gastric adenocarcinoma: The Multiethnic Cohort.
Topics: Adenocarcinoma; Aspirin; Cohort Studies; Diet; Diet, Mediterranean; Humans; Risk Factors; Stomach Ne | 2023 |
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo | 2023 |
Intermittent Dosing Regimens of Aspirin and Naproxen Inhibit Azoxymethane-Induced Colon Adenoma Progression to Adenocarcinoma and Invasive Carcinoma.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azoxymethane; Ca | 2019 |
Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Fe | 2019 |
Antiproliferative potential of Andean Berry (Vaccinium meridionale Swartz) juice in combination with Aspirin in human SW480 colon adenocarcinoma cells.
Topics: Adenocarcinoma; Aspirin; Colon; Fruit; Humans; Vaccinium | 2021 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Lin | 2021 |
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Gastro | 2017 |
Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; | 2018 |
Should aspirin and PPIs be recommended for patients with Barrett's oesophagus?
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Esophageal Neoplasms; Esophagus; Humans; Proton Pump Inh | 2018 |
Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study.
Topics: Adenocarcinoma; Adult; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroida | 2019 |
Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cohort Studies; Colorectal Neopla | 2019 |
Mechanisms of the anti-proliferative and anti-inflammatory effects of the herbal fixed combination STW 5 (Iberogast®) on colon adenocarcinoma (HT29) cells in vitro.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; bcl-2-Associated X Prot | 2013 |
Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; | 2013 |
Low-dose aspirin use and cancer characteristics: a population-based cohort study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Breast Neoplasms; Cohort Studies; | 2013 |
A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot | 2013 |
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Aspirin; Barrett Esophagus; Case-Control Studies; Chemoprev | 2014 |
The comparative study of acetyl-11-keto-beta-boswellic acid (AKBA) and aspirin in the prevention of intestinal adenomatous polyposis in APC(Min/+) mice.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Administration, Oral; Animals; Anti-Inflammatory Agents; | 2014 |
[Case of cardiac tamponade during the treatment of acute cerebral infarction].
Topics: Acute Disease; Adenocarcinoma; Anterior Cerebral Artery; Antipyrine; Aspirin; Cardiac Tamponade; Cer | 2014 |
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea | 2014 |
Is aspirin for colorectal cancer prevention on the prime time yet?
Topics: Adenocarcinoma; Adenoma; Anticarcinogenic Agents; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2014 |
Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Cell Cycle; Ce | 2014 |
Risk factors for early and delayed post-operative bleeding after endoscopic submucosal dissection of gastric neoplasms, including patients with continued use of antithrombotic agents.
Topics: Adenocarcinoma; Aged; Aspirin; Dissection; Female; Fibrinolytic Agents; Gastric Mucosa; Gastroscopy; | 2014 |
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Control St | 2015 |
Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Azo Compounds; | 2015 |
Aspirin and Acetaminophen Use and the Risk of Cervical Cancer.
Topics: Acetaminophen; Adenocarcinoma; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non- | 2015 |
Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Breast Neoplas | 2015 |
Cancers prevented in Australia in 2010 through the consumption of aspirin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Aspirin; Australia; Carcinoma, Squamous Cell; Colore | 2015 |
Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cerebr | 2016 |
Effect of statin and aspirin use on toxicity and pathological complete response rate of neo-adjuvant chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ch | 2016 |
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diabetes Mellit | 2016 |
Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase 3; Cel | 2016 |
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; | 2016 |
Inhibition of the Biosynthesis of Prostaglandin E2 By Low-Dose Aspirin: Implications for Adenocarcinoma Metastasis.
Topics: Adenocarcinoma; Adult; Aspirin; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinop | 2016 |
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont | 2016 |
Aspirin-induced mucosal cell death in human gastric cells: role of a caspase-independent mechanism.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Apoptosis Inducing Factor; Aspir | 2009 |
Chemoprevention and Barrett's esophagus: decisions, decisions.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Patient preferences for the chemoprevention of esophageal adenocarcinoma in Barrett's esophagus.
Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cardiovascular Diseases; Celecoxib; Chemoprevention; Cyc | 2008 |
Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Aspirin; Cell Line, Tumor; Chenodeoxycholic Acid; Cholagogues | 2008 |
Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Female | 2009 |
[Effect of arsenic trioxide combined with aspirin on the growth of human gastric adenocarcinoma graft in nude mice].
Topics: Adenocarcinoma; Animals; Arsenic Trioxide; Arsenicals; Aspirin; bcl-2-Associated X Protein; Humans; | 2009 |
Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth.
Topics: Adenocarcinoma; Apoptosis; Aspirin; bcl-X Protein; Cell Cycle; Cell Line, Tumor; Cell Proliferation; | 2009 |
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2010 |
Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Algorithms; Anticarcinogenic Agents; Aspirin; Calibration; Cost-Benefit Analy | 2010 |
Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Calcium; Cell Line, Tumor; | 2010 |
Hemorrhagic cholecystitis after anticoagulation therapy.
Topics: Adenocarcinoma; Aged; Angina, Unstable; Anticoagulants; Aspirin; Cholecystitis; Female; Gallbladder | 2010 |
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cell Growth Processes; | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop | 2011 |
Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colorectal Neoplasms; Dose-R | 2011 |
Killing two birds with one salicylate: aspirin's dual roles in preventative health.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anticarcinogenic Agents; Aspirin; Cardiovascular Agents; Car | 2011 |
Aspirin use and bleeding risk after endoscopic submucosal dissection in patients with gastric neoplasms.
Topics: Adenocarcinoma; Adenoma; Aged; Aspirin; Cardiovascular Diseases; Female; Gastric Mucosa; Gastrointes | 2012 |
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett E | 2012 |
Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Antineoplastic | 2012 |
Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chemoprevention; Clopidogre | 2012 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Asp | 2013 |
Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
Topics: Acetaminophen; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Divis | 2002 |
Relationship between apoptosis, angiogenesis and colon-26 tumour growth after oral NSAID-treatment.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; A | 2002 |
NCX 4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Aspirin; Cell Cycle; Cell Division; Cell Survival; Colonic | 2003 |
Prostaglandin-independent effects of aspirin on cell cycle and putrescine synthesis in human colon carcinoma cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Caco-2 Ce | 2003 |
[Inhibition effect of aspirin on the growth of gastric cancer and the mechanism there-in involved].
Topics: Adenocarcinoma; Aspirin; Cell Division; Cyclooxygenase 2; Humans; Isoenzymes; Membrane Proteins; Pro | 2003 |
[Effects of NaBT and NSAIDs on colorectal adenoma-carcinoma cells].
Topics: Adenocarcinoma; Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Cel | 2003 |
NSAIDS and esophageal cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Squamous Cell; Esophage | 2003 |
Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Cost-Benefit Analysis; D | 2004 |
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Humans; Intesti | 2004 |
Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Female; | 2005 |
Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tu | 2005 |
NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells.
Topics: Adenocarcinoma; Aspirin; Base Sequence; Catalysis; Colonic Neoplasms; DNA Primers; HT29 Cells; Human | 2005 |
NO-donating aspirin induces phase II enzymes in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Aspirin; Chemoprevention; Colonic Neoplasms; Enzyme Induction; Female; Glut | 2006 |
Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress.
Topics: Adenocarcinoma; Adherens Junctions; Animals; Antineoplastic Agents; Apoptosis; Aspirin; beta Catenin | 2005 |
Inhibition of human telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon carcinoma.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Colonic Neoplas | 2006 |
Regular aspirin use and esophageal cancer risk.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Car | 2006 |
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Topics: Acetaminophen; Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2006 |
Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase 9; Cell Cycle; | 2006 |
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Barrett Esophagus; Casp | 2006 |
Aspirin-induced apoptosis in human gastric cancer epithelial cells: relationship with protein kinase C signaling.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspases; Cell Line, Tu | 2007 |
Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Biomarkers, Tum | 2007 |
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colore | 2007 |
NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aspirin; Cell Line, Tumor; Cell Proliferation; Femal | 2008 |
Regular adult aspirin use decreases the risk of non-small cell lung cancer among women.
Topics: Acetaminophen; Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body M | 2008 |
Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells.
Topics: 4-Butyrolactone; Adenocarcinoma; Aspirin; Caco-2 Cells; Cell Growth Processes; Colonic Neoplasms; Cy | 2008 |
Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus.
Topics: Acetaminophen; Adenocarcinoma; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2008 |
Effects of sodium chloride, saccharin, phenobarbital and aspirin on gastric carcinogenesis in rats after initiation with N-methyl-N'-nitro-N-nitrosoguanidine.
Topics: Adenocarcinoma; Animals; Aspirin; Carcinogens; Male; Methylnitronitrosoguanidine; Phenobarbital; Rat | 1984 |
Cocarcinogenic action of aspirin on gastric tumors induced by N-nitroso-N-methylnitroguanidine in rats.
Topics: Adenocarcinoma; Animals; Aspirin; Carcinoma, Squamous Cell; Cocarcinogenesis; Female; Humans; Male; | 1983 |
Experimental models for gastric leiomyosarcoma. The effects of N-methyl-N'-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate.
Topics: Adenocarcinoma; Animals; Aspirin; Cocarcinogenesis; Diet; Disease Models, Animal; Leiomyosarcoma; Ma | 1984 |
Characterization of the platelet-aggregating activity of tumor cells.
Topics: Adenocarcinoma; Adenosine Diphosphate; Animals; Aspirin; Cell Line; Cell Membrane; Growth Substances | 1980 |
[A report of two endometrial cancer cases in that low-dose aspirin was effective for hypercoagulopathy caused by medroxyprogesterone acetate].
Topics: Adenocarcinoma; Adult; Aspirin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; M | 1995 |
Prostaglandin E2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Aspirin; Base Sequence; Cell Line; Colonic Neoplasms; Dinoprost; Dinoprostone; DNA P | 1995 |
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Body Weight; Colon | 1993 |
Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; CDC2 Protein Kinase; CD | 1996 |
Low molecular weight heparin-induced thrombocytopenia and thrombosis.
Topics: Adenocarcinoma; Aged; Arterial Occlusive Diseases; Aspirin; Dextrans; Embolism; Female; Femoral Arte | 1996 |
Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia.
Topics: Adenocarcinoma; Adenoma; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 1996 |
Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation.
Topics: Adenocarcinoma; Aspirin; Cell Division; Humans; Hydroxyeicosatetraenoic Acids; Lung Neoplasms; Neutr | 1996 |
[Does regular administration of aspirin reduce the risk of gastrointestinal carcinomas?].
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; | 1996 |
Effect of aspirin on cell proliferation and differentiation of colon adenocarcinoma Caco-2 cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein A-I; Apoptosis; Aspirin; Blo | 1997 |
Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; | 1998 |
Acromegaly and colonic cancer.
Topics: Acromegaly; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Col | 1997 |
Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cell Transforma | 1998 |
Aspirin use and p53 expression in colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aspirin; Colorectal Neoplasms; Female; Gene Expression R | 1998 |
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Aspirin; Azoxymethane; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase | 1998 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
Cell-type-specific activation of c-Jun N-terminal kinase by salicylates.
Topics: Acetaminophen; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium-Ca | 1999 |
Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months.
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Adipose Tissue; alpha-Amylases; Animals; Anti-I | 1999 |
Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia.
Topics: Adenocarcinoma; Aged; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, | 1999 |
Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells.
Topics: Adenocarcinoma; Adenoviruses, Human; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Ce | 2000 |
Beta-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas.
Topics: Adenocarcinoma; Adrenergic beta-Antagonists; Arachidonic Acid; Aspirin; Base Sequence; DNA Primers; | 2001 |
Aspirin and risk for gastric cancer: a population-based case-control study in Sweden.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; | 2001 |
Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin | 2001 |
[The effects of butyrates and non-steroidal anti-inflammatory agents on HT-29 colonic carcinoma cells].
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Butyrates; Colonic Neop | 2002 |
Inhibitory effect of acetylsalicylic acid on metalloproteinase activity in human lung adenocarcinoma at different stages of differentiation.
Topics: Adenocarcinoma; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents | 2002 |
Reduced growth rate of transplantable mammary adenocarcinoma in C3H mice fed eicosa-5,8,11,14-tetraynoic acid.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Adenocarcinoma; Animals; Arachidonic Acids; Aspirin; Dietary Fats; | 1977 |
Investigations on prostatic adenocarcinomas in rats.
Topics: Adenocarcinoma; Anesthetics; Animals; Aspirin; Cell Line; Female; Immunotherapy; Indomethacin; Lung | 1977 |
Platelet and shear rate promote tumor cell adhesion to human endothelial extracellular matrix--absence of a role for platelet cyclooxygenase.
Topics: Adenocarcinoma; Aspirin; Blood Flow Velocity; Blood Platelets; Cell Adhesion; Cell Line; Endothelium | 1989 |
[Mortality and morbidity of thromboembolism in drug prevention--5-year analysis].
Topics: Adenocarcinoma; Adult; Aspirin; Cesarean Section; Dihydroergotamine; Female; Genital Diseases, Femal | 1988 |
Haematological effects of aspirin.
Topics: Adenocarcinoma; Animals; Aspirin; Heparin; Lung Neoplasms; Mice; Neoplasm Metastasis; Neoplasms, Exp | 1972 |
Anti-metastatic effect of aspirin.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aspirin; Fibrosarcoma; Humans; Mice; Neoplasm Metast | 1972 |
Cancer and upper gastrointestinal tract hemorrhage. Benign causes of bleeding demonstrated by endoscopy.
Topics: Acute Disease; Adenocarcinoma; Aspirin; Chronic Disease; Endoscopy; Esophageal and Gastric Varices; | 1973 |
Renal pelvic tumour associated with analgesic abuse.
Topics: Adenocarcinoma; Aged; Alcoholism; Analgesics; Aspirin; Caffeine; Codeine; Drug Synergism; Female; Hu | 1972 |
Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease.
Topics: Adenocarcinoma; Animals; Aspirin; Blood Cell Count; Blood Platelets; Carcinoma; Cell Survival; Chrom | 1973 |